SCHEMBL17912895

SCHEMBL17912895

O=C1NCCN1c1cc(F)c(Br)cn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDO2 P48775 1/20 0.46
▸ ALOX5AP P20292 1/20 0.40
▸ FEN1 P39748 1/20 0.40
▸ CYP1A2 P05177 2/20 0.39
▸ CYP3A4 P08684 2/20 0.39
▸ TSHR P16473 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ SCN9A Q15858 2/20 0.39
▸ PARP1 P09874 2/20 0.37
▸ PIM1 P11309 2/20 0.35
▸ PIM3 Q86V86 2/20 0.35
▸ ALDH1A1 P00352 2/20 0.34
▸ POLB P06746 2/20 0.34
▸ ALOX5 P09917 1/20 0.33
▸ CCNT1 O60563 1/20 0.33
▸ CDK4 P11802 1/20 0.33
▸ CCND1 P24385 1/20 0.33
▸ CCND3 P30281 1/20 0.33
▸ CDK7 P50613 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL412734 0.74 TDO2 (0.48) TDO2ALOX5APFEN1CYP1A2CYP3A4
SCHEMBL18640602 0.73 ALDH1A1 (0.38) TDO2ALOX5APFEN1CYP1A2CYP3A4
SCHEMBL22519009 0.71 AR (0.39) TSHRALDH1A1KDM4EMAPT
SCHEMBL853306 0.69 TDO2 (0.49) TDO2ALOX5APFEN1CYP1A2CYP3A4
SCHEMBL9988948 0.68 CYP1A2 (0.44) TDO2ALOX5APFEN1CYP1A2CYP3A4
SCHEMBL19454936 0.68 TDO2 (0.48) TDO2CYP1A2CYP3A4TSHRSMN1; SMN2
SCHEMBL20909892 0.68 CCR1 (0.47) TDO2CYP3A4TSHRSMN1; SMN2ALDH1A1
SCHEMBL2190695 0.68 CCNT1 (0.44) TDO2CYP1A2CYP3A4TSHRSMN1; SMN2
SCHEMBL25191524 0.68 HTR3A (0.51) TDO2CYP1A2SMN1; SMN2
SCHEMBL31195982 0.68 CNR2 (0.46) TDO2CYP1A2TSHRSMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107406426-B Cyclic ureas as ROCK inhibitors 百时美施贵宝公司 2020-11-20 — — CN disclosed
EP-3242873-B1 CYCLIC UREAS AS INHIBITORS OF ROCK BRISTOL MYERS SQUIBB CO (US) 2020-07-22 — — EP disclosed
EP-3242873-B1 CYCLIC UREAS AS INHIBITORS OF ROCK BRISTOL MYERS SQUIBB CO (US) 2020-07-22 — — EP disclosed
US-10123993-B2 Cyclic ureas as inhibitors of rock BRISTOL-MYERS SQUIBB COMPANY (US) 2018-11-13 — — US disclosed
US-20180000788-A1 CYCLIC UREAS AS INHIBITORS OF ROCK BRISTOL MYERS SQUIBB CO (US) 2018-01-04 — — US disclosed
US-20180000788-A1 CYCLIC UREAS AS INHIBITORS OF ROCK BRISTOL MYERS SQUIBB CO (US) 2018-01-04 — — US disclosed
EP-3242873-A1 CYCLIC UREAS AS INHIBITORS OF ROCK Bristol-Myers Squibb Company (US) 2017-11-15 — — EP disclosed
WO-2016112236-A1 CYCLIC UREAS AS INHIBITORS OF ROCK BRISTOL-MYERS SQUIBB COMPANY (US) 2016-07-14 — — WO disclosed
WO-2016112236-A1 CYCLIC UREAS AS INHIBITORS OF ROCK BRISTOL-MYERS SQUIBB COMPANY (US) 2016-07-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10123993-B2 Cyclic ureas as inhibitors of rock MYLK, ROCK1, UACA TDO2 4050/4885ALOX5AP 1672/4885FEN1 858/4885
US-20180000788-A1 CYCLIC UREAS AS INHIBITORS OF ROCK MYLK, ROCK1, UACA TDO2 4050/4885ALOX5AP 1672/4885FEN1 858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback